Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells

The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens...

Full description

Saved in:

Bibliographic Details
Published in:	Cellular & molecular immunology Vol. 14; no. 4; pp. 360 - 370
Main Authors:	Fehres, Cynthia M, Duinkerken, Sanne, Bruijns, Sven CM, Kalay, Hakan, van Vliet, Sandra J, Ambrosini, Martino, de Gruijl, Tanja D, Unger, Wendy WJ, Garcia-Vallejo, Juan J, van Kooyk, Yvette
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.04.2017 Nature Publishing Group
Subjects:	Antibodies Antibodies - metabolism Antigen presentation Antigen-presenting cells Antigens Antigens - metabolism Antigens, CD - metabolism Antiviral agents Biomedical and Life Sciences Biomedicine CD8 antigen Cell Compartmentation Cell Differentiation - drug effects Cross-Priming - drug effects Cross-Priming - immunology Cytotoxicity Endocytosis - drug effects Endosomes Endosomes - drug effects Endosomes - metabolism Humans Immunology Immunotherapy Internalization Langerhans cells Langerhans Cells - cytology Langerhans Cells - drug effects Langerhans Cells - metabolism Lectins, C-Type - metabolism Ligands Lymphocytes T Mannose-Binding Lectins - metabolism Medical Microbiology Microbiology Peptides Peptides - metabolism Poly I-C - pharmacology Proteolysis research-article Skin Skin - metabolism TLR3 protein Toll-like receptors Toll-Like Receptors - metabolism Toll样受体 Tumors Vaccination Vaccine 人类介导修饰内化抗原呈递早期细胞亚群 early endosomes langerin human Langerhans cells dectin-1 antigen cross-presentation
ISSN:	1672-7681, 2042-0226, 2042-0226
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8^＋ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells （LCs） were able to cross-present a synthetic long peptide （SLP） to CD8^＋ T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1 ^＋ early endosomes. The potency of LCs to enhance CD8^＋ T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic：polycytidylic acid （phC）. Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses.
AbstractList	The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8+ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells (LCs) were able to cross-present a synthetic long peptide (SLP) to CD8 + T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1 + early endosomes. The potency of LCs to enhance CD8 + T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic:polycytidylic acid (pI:C). Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses. The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8+ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells (LCs) were able to cross-present a synthetic long peptide (SLP) to CD8 super(+) T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1 super(+) early endosomes. The potency of LCs to enhance CD8 super(+) T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic:polycytidylic acid (pI:C). Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses. The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8+ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells (LCs) were able to cross-present a synthetic long peptide (SLP) to CD8+ T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1+ early endosomes. The potency of LCs to enhance CD8+ T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic:polycytidylic acid (pI:C). Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses. The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8+ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells (LCs) were able to cross-present a synthetic long peptide (SLP) to CD8+ T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1+ early endosomes. The potency of LCs to enhance CD8+ T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic:polycytidylic acid (pI:C). Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses.The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8+ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells (LCs) were able to cross-present a synthetic long peptide (SLP) to CD8+ T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1+ early endosomes. The potency of LCs to enhance CD8+ T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic:polycytidylic acid (pI:C). Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses. The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8+ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells (LCs) were able to cross-present a synthetic long peptide (SLP) to CD8 T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1 early endosomes. The potency of LCs to enhance CD8 T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic:polycytidylic acid (pI:C). Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses. The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8^＋ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells （LCs） were able to cross-present a synthetic long peptide （SLP） to CD8^＋ T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1 ^＋ early endosomes. The potency of LCs to enhance CD8^＋ T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic：polycytidylic acid （phC）. Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses.
Author	Cynthia M Fehres Sanne Duinkerken Sven CM Bruijns Hakan Kalay Sandra J van Vliet Martino Ambrosini Tanja D de Gruijl Wendy WJ Unger Juan J Garcia-Vallejo Yvette van Kooyk
AuthorAffiliation	Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, the Netherlands Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands
Author_xml	– sequence: 1 givenname: Cynthia M surname: Fehres fullname: Fehres, Cynthia M organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center – sequence: 2 givenname: Sanne surname: Duinkerken fullname: Duinkerken, Sanne organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center – sequence: 3 givenname: Sven CM surname: Bruijns fullname: Bruijns, Sven CM organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center – sequence: 4 givenname: Hakan surname: Kalay fullname: Kalay, Hakan organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center – sequence: 5 givenname: Sandra J surname: van Vliet fullname: van Vliet, Sandra J organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center – sequence: 6 givenname: Martino surname: Ambrosini fullname: Ambrosini, Martino organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center – sequence: 7 givenname: Tanja D surname: de Gruijl fullname: de Gruijl, Tanja D organization: Department of Medical Oncology, VU University Medical Center – sequence: 8 givenname: Wendy WJ surname: Unger fullname: Unger, Wendy WJ organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center – sequence: 9 givenname: Juan J surname: Garcia-Vallejo fullname: Garcia-Vallejo, Juan J organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center – sequence: 10 givenname: Yvette surname: van Kooyk fullname: van Kooyk, Yvette email: y.vankooyk@vumc.nl organization: Department of Molecular Cell Biology and Immunology,VU University Medical Center
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/26456691$$D View this record in MEDLINE/PubMed
BookMark	eNqNkk1r3DAQhkVJaTZpT70X0V4Crbf6siRfCiX0CxZ6ac9Ca493FWxpI9mF7e_oD4683oQ0hNKTGOaZV_Pyzhk68cEDQi8pWVLC9fu6d0tGaLnU6glaMCJYQRiTJ2hBpWKFkpqeorOUrggptVDiGTplUpRSVnSB_qys30B0vuihcXaABjs_QPS2c7_t4ILHocUW96FxrcvdHewG1wCOYRwgYesHtwGf8BAw2NjtMfgmpNAfek2uttbXuahjSKnYRUjgh1l4vcfbsbcezztkMGPQdek5etraLsGL43uOfn7-9OPya7H6_uXb5cdVUUtChmK9FrbWQKhVpWpUTRrBrS6hlVzaWlJOQAAAp5ZyK9a85URkTFciDwjS8HP0Ydbdjetsv86bRduZXXS9jXsTrDN_d7zbmk34ZUquSSVoFrg4CsRwPUIaTO_SZMF6CGMyVFeKq0pp_R8ok1KI8qD65gF6FcYpkWSYkoRXguTg_0Hlb5kiTJUyU6_uW7zzdnsBGaAzcAgoQmtqN-eTHbvOUGKmKzP5ysx0ZUarPPP2wcyt7OP0u5lOmZqCvrfoo_jro_g2-M11nrhTl4pqWpVC8hvmk_Ax
CitedBy_id	crossref_primary_10_1039_D3NH00063J crossref_primary_10_1186_s40164_023_00469_0 crossref_primary_10_3389_fimmu_2024_1504886 crossref_primary_10_1089_vim_2017_0146 crossref_primary_10_1189_jlb_5MR0217_059RR crossref_primary_10_3389_fimmu_2021_732298 crossref_primary_10_1016_j_jconrel_2021_03_027 crossref_primary_10_1111_jcmm_15834 crossref_primary_10_4049_jimmunol_1701402 crossref_primary_10_3390_pharmaceutics11110612 crossref_primary_10_1002_dni2_70002 crossref_primary_10_3390_vaccines10122049 crossref_primary_10_1016_j_cbpa_2019_10_001 crossref_primary_10_1016_j_ijbiomac_2025_143611 crossref_primary_10_3389_fimmu_2018_00590 crossref_primary_10_1002_anie_202006880 crossref_primary_10_1016_j_copbio_2017_11_003 crossref_primary_10_1002_adma_202402580 crossref_primary_10_3389_fcell_2020_00556 crossref_primary_10_3389_fimmu_2023_1294929 crossref_primary_10_1016_j_jneuroim_2021_577792 crossref_primary_10_1002_eji_202250340 crossref_primary_10_3389_fimmu_2022_918190 crossref_primary_10_1111_jdv_20291 crossref_primary_10_1016_j_smim_2023_101764 crossref_primary_10_3390_pharmaceutics12020153 crossref_primary_10_3389_fimmu_2018_00884 crossref_primary_10_3389_fimmu_2023_1080238 crossref_primary_10_3390_cancers12113428 crossref_primary_10_1002_ange_202006880
Cites_doi	10.1038/jid.2009.424 10.1038/nri2173 10.1182/blood-2010-01-264960 10.1016/j.jconrel.2012.02.007 10.1038/nm1541 10.4049/jimmunol.177.11.7959 10.1084/jem.20092618 10.1016/j.immuni.2004.07.004 10.1385/IR:28:2:93 10.1182/blood-2011-03-344838 10.1084/jem.20111457 10.1002/j.1460-2075.1986.tb04307.x 10.1016/j.jconrel.2015.01.040 10.1084/jem.20021598 10.1189/jlb.1HI0714-351R 10.1084/jem.20092140 10.1016/j.jmb.2010.11.039 10.1016/j.coi.2012.11.007 10.1038/nri3254 10.1111/j.0105-2896.2004.00142.x 10.1084/jem.20112583 10.4049/jimmunol.165.8.4239 10.1016/j.immuni.2008.07.013 10.1002/eji.201041305 10.1038/jid.2011.437 10.1038/jid.2009.21 10.1038/jid.2012.26 10.1084/jem.20100348 10.1084/jem.20032220 10.1016/j.immuni.2012.03.018 10.1073/pnas.96.18.10326 10.1182/blood-2011-08-373944 10.1182/blood-2012-01-402370 10.1002/eji.201344094 10.1016/j.immuni.2011.06.005 10.1038/ni1417 10.4049/jimmunol.1102725 10.1084/jem.20091964 10.4049/jimmunol.178.4.1986 10.1038/jid.2009.343 10.1093/intimm/dxm096 10.1126/science.7809629 10.1038/14058 10.1038/ni.1602 10.1038/ni.1724 10.4049/jimmunol.1300787 10.1182/blood-2006-10-051375 10.1038/jid.2011.164
ContentType	Journal Article
Copyright	Chinese Society of Immunology and The University of Science and Technology 2015 Copyright Nature Publishing Group Apr 2017 Chinese Society of Immunology and The University of Science and Technology 2015. Copyright © 2015 Chinese Society of Immunology and The University of Science and Technology 2015 Chinese Society of Immunology and The University of Science and Technology
Copyright_xml	– notice: Chinese Society of Immunology and The University of Science and Technology 2015 – notice: Copyright Nature Publishing Group Apr 2017 – notice: Chinese Society of Immunology and The University of Science and Technology 2015. – notice: Copyright © 2015 Chinese Society of Immunology and The University of Science and Technology 2015 Chinese Society of Immunology and The University of Science and Technology
DBID	2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 7T5 H94 5PM
DOI	10.1038/cmi.2015.87
DatabaseName	维普_期刊中文科技期刊数据库-CALIS站点维普中文期刊数据库中文科技期刊数据库-医药卫生中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection (subscription) ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Immunology Abstracts AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts
DatabaseTitleList	AIDS and Cancer Research Abstracts ProQuest Central Student MEDLINE - Academic MEDLINE ProQuest Central Student
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
DocumentTitleAlternate	Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells Langerin-mediated antigen cross-presentation
EISSN	2042-0226
EndPage	370
ExternalDocumentID	PMC5380941 4322050697 26456691 10_1038_cmi_2015_87 671819546
Genre	Journal Article
GroupedDBID	--- -05 -0E -Q- -SE -S~ 0R~ 29B 2B. 2C~ 2RA 2WC 3V. 4.4 406 53G 5GY 5VR 6J9 70F 7X7 88E 8FE 8FH 8FI 8FJ 92F 92I 92L 92M 93N 93R 9D9 9DE AADWK AANZL AATNV AAWBL AAYFA AAYJO AAZLF ABAWZ ABGIJ ABJNI ABKZE ABUWG ACAOD ACBMV ACBRV ACBYP ACGFS ACIGE ACKTT ACPRK ACRQY ACTTH ACVWB ACZOJ ADFRT ADHDB ADMDM ADQMX ADYYL AEDAW AEFTE AEJRE AENEX AEVLU AEXYK AFKRA AFNRJ AFSHS AFUIB AGAYW AGEZK AGGBP AGHAI AHMBA AHSBF AILAN AJCLW AJDOV AJRNO ALMA_UNASSIGNED_HOLDINGS AMRJV AMYLF AXYYD BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CAJEE CAJUS CCEZO CCPQU CHBEP CIEJG CQIGP CW9 DIK DNIVK DPUIP DU5 EBLON EBS EE. EIOEI EJD F5P FA0 FDQFY FERAY FIZPM FRP FSGXE FYUFA GX1 HCIFZ HMCUK HYE HZ~ IWAJR JUIAU JZLTJ KQ8 LK8 M1P M7P NAO NQJWS NYICJ O9- OK1 P6G PQQKQ PROAC PSQYO Q-- Q-4 R-E RNT RNTTT RPM RT5 S.. SNX SNYQT SRMVM SWTZT T8U TAOOD TBHMF TCJ TDRGL TGQ TR2 TSG U1F U1G U5E U5O UKHRP W91 WFFXF ~88 ~MX ~WA AACDK AASML AAXDM ABAKF ABZZP AEFQL AEMSY AFBBN AGQEE AIGIU ALIPV FIGPU ROL AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB SOJ CGR CUY CVF ECM EIF NPM 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 7T5 H94 5PM
ID	FETCH-LOGICAL-c600t-bb4ac8e01a757d7c0d43a85ef636ac6130e4eee31a13a4b3f304d7c894a7540d3
IEDL.DBID	M7P
ISICitedReferencesCount	36
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000400900500005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1672-7681 2042-0226
IngestDate	Tue Nov 04 02:00:27 EST 2025 Thu Oct 02 08:21:57 EDT 2025 Mon Sep 29 04:05:04 EDT 2025 Tue Oct 07 06:36:49 EDT 2025 Sat Nov 29 14:25:51 EST 2025 Thu Apr 03 06:58:57 EDT 2025 Sat Nov 29 02:22:33 EST 2025 Tue Nov 18 21:48:57 EST 2025 Fri Feb 21 02:37:10 EST 2025 Wed Feb 14 10:02:08 EST 2024
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	early endosomes langerin human Langerhans cells dectin-1 antigen cross-presentation
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c600t-bb4ac8e01a757d7c0d43a85ef636ac6130e4eee31a13a4b3f304d7c894a7540d3
Notes	11-4987/R The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin contains several antigen-presenting cell subsets with specialized functions. In particular, the capacity to cross-present exogenous antigens to CD8^＋ T cells is of interest for the design of effective immunotherapies against viruses or cancer. Here, we show that primary human Langerhans cells （LCs） were able to cross-present a synthetic long peptide （SLP） to CD8^＋ T cells. In addition, modification of this SLP using antibodies against the receptor langerin, but not dectin-1, further enhanced the cross-presenting capacity of LCs through routing of internalized antigens to less proteolytic early endosome antigen 1 ^＋ early endosomes. The potency of LCs to enhance CD8^＋ T-cell responses could be further increased through activation of LCs with the toll-like receptor 3 ligand polyinosinic：polycytidylic acid （phC）. Altogether, the data provide evidence that human LCs are able to cross-present antigens after langerin-mediated internalization. Furthermore, the potential for antigen modification to target LCs specifically provides a rationale for generating effective anti-tumor or anti-viral cytotoxic T lymphocyte responses. antigen cross-presentation; dectin-1; early endosomes; human Langerhans cells; langerin ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://www.nature.com/articles/cmi201587.pdf
PMID	26456691
PQID	1892702756
PQPubID	2041960
PageCount	11
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_5380941 proquest_miscellaneous_1897379788 proquest_miscellaneous_1826644541 proquest_journals_2760394010 proquest_journals_1892702756 pubmed_primary_26456691 crossref_citationtrail_10_1038_cmi_2015_87 crossref_primary_10_1038_cmi_2015_87 springer_journals_10_1038_cmi_2015_87 chongqing_primary_671819546
PublicationCentury	2000
PublicationDate	2017-04-01
PublicationDateYYYYMMDD	2017-04-01
PublicationDate_xml	– month: 04 year: 2017 text: 2017-04-01 day: 01
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: China
PublicationTitle	Cellular & molecular immunology
PublicationTitleAbbrev	Cell Mol Immunol
PublicationTitleAlternate	Cellular ＆ Molecular Immunology
PublicationYear	2017
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	Heath, Belz, Behrens, Smith, Forehan, Parish (CR1) 2004; 199 Poulin, Salio, Griessinger, Anjos-Afonso, Craciun, Chen (CR42) 2010; 207 de Witte, Nabatov, Pion, Fluitsma, de Jong, de Gruijl (CR27) 2007; 13 Bigley, McGovern, Milne, Dickinson, Pagan, Cookson (CR33) 2015; 97 Seneschal, Clark, Gehad, Baecher-Allan, Kupper (CR48) 2012; 36 Bigley, McGovern, Milne, Dickinson, Pagan, Cookson (CR14) 2015; 97 Rodriguez, Regnault, Kleijmeer, Ricciardi-Castagnoli, Amigorena (CR22) 1999; 1 Crespo, Zacca, Nunez, Ranocchia, Maccioni, Maletto (CR34) 2013; 190 Valladeau, Dezutter-Dambuyant, Saeland (CR3) 2003; 28 van de Ven, van den Hout, Lindenberg, Sluijter, van Leeuwen, Lougheed (CR39) 2011; 118 Bonifaz, Bonnyay, Mahnke, Rivera, Nussenzweig, Steinman (CR35) 2002; 196 Flacher, Bouschbacher, Verronese, Massacrier, Sisirak, Berthier-Vergnes (CR36) 2006; 177 Klechevsky, Morita, Liu, Cao, Coquery, Thompson-Snipes (CR7) 2008; 29 Bachem, Guttler, Hartung, Ebstein, Schaefer, Tannert (CR40) 2010; 207 Tacken, de Vries, Torensma, Figdor (CR16) 2007; 7 Igyarto, Kaplan (CR13) 2013; 25 Unger, van Beelen, Bruijns, Joshi, Fehres, van Bloois (CR18) 2012; 160 Bonifaz, Bonnyay, Charalambous, Darguste, Fujii, Soares (CR20) 2004; 199 Bedoui, Whitney, Waithman, Eidsmo, Wakim, Caminschi (CR11) 2009; 10 Schreibelt, Klinkenberg, Cruz, Tacken, Tel, Kreutz (CR43) 2012; 119 Fehres, Kalay, Bruijns, Musaafir, Ambrosini, van Bloois (CR47) 2015; 203 Hooijberg, Ruizendaal, Snijders, Kueter, Walboomers, Spits (CR30) 2000; 165 Jongbloed, Kassianos, McDonald, Clark, Ju, Angel (CR41) 2010; 207 Henri, Poulin, Tamoutounour, Ardouin, Guilliams, de Bovis (CR12) 2010; 207 Kovacsovics-Bankowski, Rock (CR21) 1995; 267 Salter, Cresswell (CR28) 1986; 5 Igyarto, Haley, Ortner, Bobr, Gerami-Nejad, Edelson (CR10) 2011; 35 Tel, Sittig, Blom, Cruz, Schreibelt, Figdor (CR17) 2013; 191 van der Vlist, de Witte, de Vries, Litjens, de Jong, Fluitsma (CR9) 2011; 41 Chu, Ali, Karagiannis, Di, Skowera, Napolitano (CR44) 2012; 209 van der Aar, Sylva-Steenland, Bos, Kapsenberg, de Jong, Teunissen (CR37) 2007; 178 Flacher, Tripp, Stoitzner, Haid, Ebner, Del (CR45) 2010; 130 Fehres, Bruijns, van Beelen, Kalay, Ambrosini, Hooijberg (CR29) 2014; 44 Feinberg, Taylor, Razi, McBride, Knirel, Graham (CR4) 2011; 405 Di, Chatterjee, Smed-Sorensen, Clayton, Palazzo, Montes (CR24) 2008; 9 Gromme, Uytdehaag, Janssen, Calafat, van Binnendijk, Kenter (CR25) 1999; 96 Segura, Valladeau-Guilemond, Donnadieu, Sastre-Garau, Soumelis, Amigorena (CR38) 2012; 209 Klechevsky, Flamar, Cao, Blanck, Liu, O’Bar (CR46) 2010; 116 Polak, Newell, Taraban, Pickard, Healy, Friedmann (CR8) 2012; 132 Shen, Sigal, Boes, Rock (CR23) 2004; 21 Angel, Lala, Chen, Edgar, Ostrovsky, Dunbar (CR31) 2007; 19 Weck, Appel, Werth, Sinzger, Bringmann, Grunebach (CR19) 2008; 111 Romani, Brunner, Stingl (CR49) 2012; 132 Eisenwort, Jurkin, Yasmin, Bauer, Gesslbauer, Strobl (CR32) 2011; 131 Robinson, Sancho, Slack, LeibundGut-Landmann, Reis E Sousa (CR15) 2006; 7 Furio, Billard, Valladeau, Peguet-Navarro, Berthier-Vergnes (CR6) 2009; 129 Joffre, Segura, Savina, Amigorena (CR2) 2012; 12 Furio, Briotet, Journeaux, Billard, Peguet-Navarro (CR5) 2010; 130 Chatterjee, Smed-Sorensen, Cohn, Chalouni, Vandlen, Lee (CR26) 2012; 120 J Tel (BFcmi201587_CR17) 2013; 191 L Furio (BFcmi201587_CR6) 2009; 129 MM Weck (BFcmi201587_CR19) 2008; 111 CC Chu (BFcmi201587_CR44) 2012; 209 OP Joffre (BFcmi201587_CR2) 2012; 12 L Furio (BFcmi201587_CR5) 2010; 130 PJ Tacken (BFcmi201587_CR16) 2007; 7 A Rodriguez (BFcmi201587_CR22) 1999; 1 SL Jongbloed (BFcmi201587_CR41) 2010; 207 AM van der Aar (BFcmi201587_CR37) 2007; 178 S Bedoui (BFcmi201587_CR11) 2009; 10 V Flacher (BFcmi201587_CR36) 2006; 177 LF Poulin (BFcmi201587_CR42) 2010; 207 B Chatterjee (BFcmi201587_CR26) 2012; 120 CE Angel (BFcmi201587_CR31) 2007; 19 R van de Ven (BFcmi201587_CR39) 2011; 118 PT Di (BFcmi201587_CR24) 2008; 9 G Schreibelt (BFcmi201587_CR43) 2012; 119 MJ Robinson (BFcmi201587_CR15) 2006; 7 G Eisenwort (BFcmi201587_CR32) 2011; 131 BZ Igyarto (BFcmi201587_CR10) 2011; 35 H Feinberg (BFcmi201587_CR4) 2011; 405 L Bonifaz (BFcmi201587_CR35) 2002; 196 MI Crespo (BFcmi201587_CR34) 2013; 190 A Bachem (BFcmi201587_CR40) 2010; 207 V Flacher (BFcmi201587_CR45) 2010; 130 J Valladeau (BFcmi201587_CR3) 2003; 28 WR Heath (BFcmi201587_CR1) 2004; 199 J Seneschal (BFcmi201587_CR48) 2012; 36 E Klechevsky (BFcmi201587_CR7) 2008; 29 WW Unger (BFcmi201587_CR18) 2012; 160 ME Polak (BFcmi201587_CR8) 2012; 132 BZ Igyarto (BFcmi201587_CR13) 2013; 25 CM Fehres (BFcmi201587_CR29) 2014; 44 M van der Vlist (BFcmi201587_CR9) 2011; 41 LC Bonifaz (BFcmi201587_CR20) 2004; 199 L de Witte (BFcmi201587_CR27) 2007; 13 M Kovacsovics-Bankowski (BFcmi201587_CR21) 1995; 267 V Bigley (BFcmi201587_CR33) 2015; 97 CM Fehres (BFcmi201587_CR47) 2015; 203 V Bigley (BFcmi201587_CR14) 2015; 97 N Romani (BFcmi201587_CR49) 2012; 132 E Hooijberg (BFcmi201587_CR30) 2000; 165 M Gromme (BFcmi201587_CR25) 1999; 96 S Henri (BFcmi201587_CR12) 2010; 207 RD Salter (BFcmi201587_CR28) 1986; 5 L Shen (BFcmi201587_CR23) 2004; 21 E Segura (BFcmi201587_CR38) 2012; 209 E Klechevsky (BFcmi201587_CR46) 2010; 116
References_xml	– volume: 130 start-page: 1345 year: 2010 end-page: 1354 ident: CR5 article-title: Human Langerhans cells are more efficient than CD14(-)CD1c(+) dermal dendritic cells at priming naive CD4(+) T cells publication-title: J Invest Dermatol doi: 10.1038/jid.2009.424 – volume: 7 start-page: 790 year: 2007 end-page: 802 ident: CR16 article-title: Dendritic-cell immunotherapy: from loading to targeting publication-title: Nat Rev Immunol doi: 10.1038/nri2173 – volume: 116 start-page: 1685 year: 2010 end-page: 1697 ident: CR46 article-title: Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR publication-title: Blood doi: 10.1182/blood-2010-01-264960 – volume: 160 start-page: 88 year: 2012 end-page: 95 ident: CR18 article-title: Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells publication-title: J Control Release doi: 10.1016/j.jconrel.2012.02.007 – volume: 13 start-page: 367 year: 2007 end-page: 371 ident: CR27 article-title: Langerin is a natural barrier to HIV-1 transmission by Langerhans cells publication-title: Nat Med doi: 10.1038/nm1541 – volume: 177 start-page: 7959 year: 2006 end-page: 7967 ident: CR36 article-title: Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria publication-title: J Immunol doi: 10.4049/jimmunol.177.11.7959 – volume: 207 start-page: 1261 year: 2010 end-page: 1271 ident: CR42 article-title: Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells publication-title: J Exp Med doi: 10.1084/jem.20092618 – volume: 21 start-page: 155 year: 2004 end-page: 165 ident: CR23 article-title: Important role of cathepsin S in generating peptides for TAP-independent MHC class I crosspresentation publication-title: Immunity doi: 10.1016/j.immuni.2004.07.004 – volume: 28 start-page: 93 year: 2003 end-page: 107 ident: CR3 article-title: Langerin/CD207 sheds light on formation of birbeck granules and their possible function in Langerhans cells publication-title: Immunol Res doi: 10.1385/IR:28:2:93 – volume: 118 start-page: 2502 year: 2011 end-page: 2510 ident: CR39 article-title: Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation publication-title: Blood doi: 10.1182/blood-2011-03-344838 – volume: 209 start-page: 653 year: 2012 end-page: 660 ident: CR38 article-title: Characterization of resident and migratory dendritic cells in human lymph nodes publication-title: J Exp Med doi: 10.1084/jem.20111457 – volume: 5 start-page: 943 year: 1986 end-page: 949 ident: CR28 article-title: Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid publication-title: EMBO J doi: 10.1002/j.1460-2075.1986.tb04307.x – volume: 203 start-page: 67 year: 2015 end-page: 76 ident: CR47 article-title: Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens publication-title: J Control Release doi: 10.1016/j.jconrel.2015.01.040 – volume: 196 start-page: 1627 year: 2002 end-page: 1638 ident: CR35 article-title: Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance publication-title: J Exp Med doi: 10.1084/jem.20021598 – volume: 97 start-page: 627 year: 2015 end-page: 634 ident: CR33 article-title: Langerin-expressing dendritic cells in human tissues are related to CD1c+ dendritic cells and distinct from Langerhans cells and CD141 high XCR1+ dendritic cells publication-title: J Leukoc Biol doi: 10.1189/jlb.1HI0714-351R – volume: 207 start-page: 1247 year: 2010 end-page: 1260 ident: CR41 article-title: Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens publication-title: J Exp Med doi: 10.1084/jem.20092140 – volume: 405 start-page: 1027 year: 2011 end-page: 1039 ident: CR4 article-title: Structural basis for langerin recognition of diverse pathogen and mammalian glycans through a single binding site publication-title: J Mol Biol doi: 10.1016/j.jmb.2010.11.039 – volume: 25 start-page: 115 year: 2013 end-page: 119 ident: CR13 article-title: Antigen presentation by Langerhans cells publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2012.11.007 – volume: 12 start-page: 557 year: 2012 end-page: 569 ident: CR2 article-title: Cross-presentation by dendritic cells publication-title: Nat Rev Immunol doi: 10.1038/nri3254 – volume: 199 start-page: 9 year: 2004 end-page: 26 ident: CR1 article-title: Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2004.00142.x – volume: 209 start-page: 935 year: 2012 end-page: 945 ident: CR44 article-title: Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation publication-title: J Exp Med doi: 10.1084/jem.20112583 – volume: 165 start-page: 4239 year: 2000 end-page: 4245 ident: CR30 article-title: Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase publication-title: J Immunol doi: 10.4049/jimmunol.165.8.4239 – volume: 29 start-page: 497 year: 2008 end-page: 510 ident: CR7 article-title: Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells publication-title: Immunity doi: 10.1016/j.immuni.2008.07.013 – volume: 41 start-page: 2619 year: 2011 end-page: 2631 ident: CR9 article-title: Human Langerhans cells capture measles virus through Langerin and present viral antigens to CD4(+) T cells but are incapable of cross-presentation publication-title: Eur J Immunol doi: 10.1002/eji.201041305 – volume: 132 start-page: 872 year: 2012 end-page: 881 ident: CR49 article-title: Changing views of the role of Langerhans cells publication-title: J Invest Dermatol doi: 10.1038/jid.2011.437 – volume: 129 start-page: 1963 year: 2009 end-page: 1971 ident: CR6 article-title: Poly(I:C)-Treated human Langerhans cells promote the differentiation of CD4+ T cells producing IFN-gamma and IL-10 publication-title: J Invest Dermatol doi: 10.1038/jid.2009.21 – volume: 132 start-page: 1636 year: 2012 end-page: 1644 ident: CR8 article-title: CD70-CD27 interaction augments CD8+ T-cell activation by human epidermal Langerhans cells publication-title: J Invest Dermatol doi: 10.1038/jid.2012.26 – volume: 207 start-page: 1273 year: 2010 end-page: 1281 ident: CR40 article-title: Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells publication-title: J Exp Med doi: 10.1084/jem.20100348 – volume: 199 start-page: 815 year: 2004 end-page: 824 ident: CR20 article-title: targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination publication-title: J Exp Med doi: 10.1084/jem.20032220 – volume: 36 start-page: 873 year: 2012 end-page: 884 ident: CR48 article-title: Human epidermal Langerhans cells maintain immune homeostasis in skin by activating skin resident regulatory T cells publication-title: Immunity doi: 10.1016/j.immuni.2012.03.018 – volume: 96 start-page: 10326 year: 1999 end-page: 10331 ident: CR25 article-title: Recycling MHC class I molecules and endosomal peptide loading publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.96.18.10326 – volume: 119 start-page: 2284 year: 2012 end-page: 2292 ident: CR43 article-title: The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells publication-title: Blood doi: 10.1182/blood-2011-08-373944 – volume: 120 start-page: 2011 year: 2012 end-page: 20 ident: CR26 article-title: Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells publication-title: Blood doi: 10.1182/blood-2012-01-402370 – volume: 44 start-page: 2415 year: 2014 end-page: 2424 ident: CR29 article-title: Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming publication-title: Eur J Immunol doi: 10.1002/eji.201344094 – volume: 35 start-page: 260 year: 2011 end-page: 272 ident: CR10 article-title: Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses publication-title: Immunity doi: 10.1016/j.immuni.2011.06.005 – volume: 7 start-page: 1258 year: 2006 end-page: 1265 ident: CR15 article-title: Myeloid C-type lectins in innate immunity publication-title: Nat Immunol doi: 10.1038/ni1417 – volume: 190 start-page: 948 year: 2013 end-page: 960 ident: CR34 article-title: TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8alpha+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface publication-title: J Immunol doi: 10.4049/jimmunol.1102725 – volume: 207 start-page: 189 year: 2010 end-page: 206 ident: CR12 article-title: CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells publication-title: J Exp Med doi: 10.1084/jem.20091964 – volume: 97 start-page: 627 year: 2015 end-page: 634 ident: CR14 article-title: Langerin-expressing dendritic cells in human tissues are related to CD1c+ dendritic cells and distinct from Langerhans cells and CD141 high XCR1+ dendritic cells publication-title: J Leukoc Biol doi: 10.1189/jlb.1HI0714-351R – volume: 178 start-page: 1986 year: 2007 end-page: 1990 ident: CR37 article-title: Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition publication-title: J Immunol doi: 10.4049/jimmunol.178.4.1986 – volume: 130 start-page: 755 year: 2010 end-page: 762 ident: CR45 article-title: Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis publication-title: J Invest Dermatol doi: 10.1038/jid.2009.343 – volume: 19 start-page: 1271 year: 2007 end-page: 1279 ident: CR31 article-title: CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts publication-title: Int Immunol doi: 10.1093/intimm/dxm096 – volume: 267 start-page: 243 year: 1995 end-page: 246 ident: CR21 article-title: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules publication-title: Science doi: 10.1126/science.7809629 – volume: 1 start-page: 362 year: 1999 end-page: 368 ident: CR22 article-title: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells publication-title: Nat Cell Biol doi: 10.1038/14058 – volume: 9 start-page: 551 year: 2008 end-page: 557 ident: CR24 article-title: Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I publication-title: Nat Immunol doi: 10.1038/ni.1602 – volume: 10 start-page: 488 year: 2009 end-page: 495 ident: CR11 article-title: Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells publication-title: Nat Immunol doi: 10.1038/ni.1724 – volume: 191 start-page: 5005 year: 2013 end-page: 5012 ident: CR17 article-title: Targeting uptake receptors on human plasmacytoid dendritic cells triggers antigen cross-presentation and robust type I IFN secretion publication-title: J Immunol doi: 10.4049/jimmunol.1300787 – volume: 111 start-page: 4264 year: 2008 end-page: 4272 ident: CR19 article-title: hDectin-1 is involved in uptake and cross-presentation of cellular antigens publication-title: Blood doi: 10.1182/blood-2006-10-051375 – volume: 131 start-page: 2049 year: 2011 end-page: 2057 ident: CR32 article-title: Identification of TROP2 (TACSTD2), an EpCAM-like molecule, as a specific marker for TGF-beta1-dependent human epidermal Langerhans cells publication-title: J Invest Dermatol doi: 10.1038/jid.2011.164 – volume: 160 start-page: 88 year: 2012 ident: BFcmi201587_CR18 publication-title: J Control Release doi: 10.1016/j.jconrel.2012.02.007 – volume: 111 start-page: 4264 year: 2008 ident: BFcmi201587_CR19 publication-title: Blood doi: 10.1182/blood-2006-10-051375 – volume: 209 start-page: 653 year: 2012 ident: BFcmi201587_CR38 publication-title: J Exp Med doi: 10.1084/jem.20111457 – volume: 267 start-page: 243 year: 1995 ident: BFcmi201587_CR21 publication-title: Science doi: 10.1126/science.7809629 – volume: 405 start-page: 1027 year: 2011 ident: BFcmi201587_CR4 publication-title: J Mol Biol doi: 10.1016/j.jmb.2010.11.039 – volume: 10 start-page: 488 year: 2009 ident: BFcmi201587_CR11 publication-title: Nat Immunol doi: 10.1038/ni.1724 – volume: 96 start-page: 10326 year: 1999 ident: BFcmi201587_CR25 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.96.18.10326 – volume: 7 start-page: 790 year: 2007 ident: BFcmi201587_CR16 publication-title: Nat Rev Immunol doi: 10.1038/nri2173 – volume: 1 start-page: 362 year: 1999 ident: BFcmi201587_CR22 publication-title: Nat Cell Biol doi: 10.1038/14058 – volume: 13 start-page: 367 year: 2007 ident: BFcmi201587_CR27 publication-title: Nat Med doi: 10.1038/nm1541 – volume: 199 start-page: 815 year: 2004 ident: BFcmi201587_CR20 publication-title: J Exp Med doi: 10.1084/jem.20032220 – volume: 130 start-page: 755 year: 2010 ident: BFcmi201587_CR45 publication-title: J Invest Dermatol doi: 10.1038/jid.2009.343 – volume: 129 start-page: 1963 year: 2009 ident: BFcmi201587_CR6 publication-title: J Invest Dermatol doi: 10.1038/jid.2009.21 – volume: 97 start-page: 627 year: 2015 ident: BFcmi201587_CR14 publication-title: J Leukoc Biol doi: 10.1189/jlb.1HI0714-351R – volume: 132 start-page: 872 year: 2012 ident: BFcmi201587_CR49 publication-title: J Invest Dermatol doi: 10.1038/jid.2011.437 – volume: 29 start-page: 497 year: 2008 ident: BFcmi201587_CR7 publication-title: Immunity doi: 10.1016/j.immuni.2008.07.013 – volume: 119 start-page: 2284 year: 2012 ident: BFcmi201587_CR43 publication-title: Blood doi: 10.1182/blood-2011-08-373944 – volume: 21 start-page: 155 year: 2004 ident: BFcmi201587_CR23 publication-title: Immunity doi: 10.1016/j.immuni.2004.07.004 – volume: 178 start-page: 1986 year: 2007 ident: BFcmi201587_CR37 publication-title: J Immunol doi: 10.4049/jimmunol.178.4.1986 – volume: 209 start-page: 935 year: 2012 ident: BFcmi201587_CR44 publication-title: J Exp Med doi: 10.1084/jem.20112583 – volume: 5 start-page: 943 year: 1986 ident: BFcmi201587_CR28 publication-title: EMBO J doi: 10.1002/j.1460-2075.1986.tb04307.x – volume: 9 start-page: 551 year: 2008 ident: BFcmi201587_CR24 publication-title: Nat Immunol doi: 10.1038/ni.1602 – volume: 44 start-page: 2415 year: 2014 ident: BFcmi201587_CR29 publication-title: Eur J Immunol doi: 10.1002/eji.201344094 – volume: 116 start-page: 1685 year: 2010 ident: BFcmi201587_CR46 publication-title: Blood doi: 10.1182/blood-2010-01-264960 – volume: 28 start-page: 93 year: 2003 ident: BFcmi201587_CR3 publication-title: Immunol Res doi: 10.1385/IR:28:2:93 – volume: 25 start-page: 115 year: 2013 ident: BFcmi201587_CR13 publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2012.11.007 – volume: 131 start-page: 2049 year: 2011 ident: BFcmi201587_CR32 publication-title: J Invest Dermatol doi: 10.1038/jid.2011.164 – volume: 207 start-page: 1261 year: 2010 ident: BFcmi201587_CR42 publication-title: J Exp Med doi: 10.1084/jem.20092618 – volume: 36 start-page: 873 year: 2012 ident: BFcmi201587_CR48 publication-title: Immunity doi: 10.1016/j.immuni.2012.03.018 – volume: 207 start-page: 1247 year: 2010 ident: BFcmi201587_CR41 publication-title: J Exp Med doi: 10.1084/jem.20092140 – volume: 7 start-page: 1258 year: 2006 ident: BFcmi201587_CR15 publication-title: Nat Immunol doi: 10.1038/ni1417 – volume: 19 start-page: 1271 year: 2007 ident: BFcmi201587_CR31 publication-title: Int Immunol doi: 10.1093/intimm/dxm096 – volume: 165 start-page: 4239 year: 2000 ident: BFcmi201587_CR30 publication-title: J Immunol doi: 10.4049/jimmunol.165.8.4239 – volume: 207 start-page: 189 year: 2010 ident: BFcmi201587_CR12 publication-title: J Exp Med doi: 10.1084/jem.20091964 – volume: 177 start-page: 7959 year: 2006 ident: BFcmi201587_CR36 publication-title: J Immunol doi: 10.4049/jimmunol.177.11.7959 – volume: 130 start-page: 1345 year: 2010 ident: BFcmi201587_CR5 publication-title: J Invest Dermatol doi: 10.1038/jid.2009.424 – volume: 132 start-page: 1636 year: 2012 ident: BFcmi201587_CR8 publication-title: J Invest Dermatol doi: 10.1038/jid.2012.26 – volume: 120 start-page: 2011 year: 2012 ident: BFcmi201587_CR26 publication-title: Blood doi: 10.1182/blood-2012-01-402370 – volume: 207 start-page: 1273 year: 2010 ident: BFcmi201587_CR40 publication-title: J Exp Med doi: 10.1084/jem.20100348 – volume: 41 start-page: 2619 year: 2011 ident: BFcmi201587_CR9 publication-title: Eur J Immunol doi: 10.1002/eji.201041305 – volume: 203 start-page: 67 year: 2015 ident: BFcmi201587_CR47 publication-title: J Control Release doi: 10.1016/j.jconrel.2015.01.040 – volume: 191 start-page: 5005 year: 2013 ident: BFcmi201587_CR17 publication-title: J Immunol doi: 10.4049/jimmunol.1300787 – volume: 190 start-page: 948 year: 2013 ident: BFcmi201587_CR34 publication-title: J Immunol doi: 10.4049/jimmunol.1102725 – volume: 35 start-page: 260 year: 2011 ident: BFcmi201587_CR10 publication-title: Immunity doi: 10.1016/j.immuni.2011.06.005 – volume: 97 start-page: 627 year: 2015 ident: BFcmi201587_CR33 publication-title: J Leukoc Biol doi: 10.1189/jlb.1HI0714-351R – volume: 12 start-page: 557 year: 2012 ident: BFcmi201587_CR2 publication-title: Nat Rev Immunol doi: 10.1038/nri3254 – volume: 196 start-page: 1627 year: 2002 ident: BFcmi201587_CR35 publication-title: J Exp Med doi: 10.1084/jem.20021598 – volume: 118 start-page: 2502 year: 2011 ident: BFcmi201587_CR39 publication-title: Blood doi: 10.1182/blood-2011-03-344838 – volume: 199 start-page: 9 year: 2004 ident: BFcmi201587_CR1 publication-title: Immunol Rev doi: 10.1111/j.0105-2896.2004.00142.x
SSID	ssj0058474
Score	2.3050294
Snippet	The potential of the skin immune system to generate immune responses is well established, and the skin is actively exploited as a vaccination site. Human skin...
SourceID	pubmedcentral proquest pubmed crossref springer chongqing
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	360
SubjectTerms	Antibodies Antibodies - metabolism Antigen presentation Antigen-presenting cells Antigens Antigens - metabolism Antigens, CD - metabolism Antiviral agents Biomedical and Life Sciences Biomedicine CD8 antigen Cell Compartmentation Cell Differentiation - drug effects Cross-Priming - drug effects Cross-Priming - immunology Cytotoxicity Endocytosis - drug effects Endosomes Endosomes - drug effects Endosomes - metabolism Humans Immunology Immunotherapy Internalization Langerhans cells Langerhans Cells - cytology Langerhans Cells - drug effects Langerhans Cells - metabolism Lectins, C-Type - metabolism Ligands Lymphocytes T Mannose-Binding Lectins - metabolism Medical Microbiology Microbiology Peptides Peptides - metabolism Poly I-C - pharmacology Proteolysis research-article Skin Skin - metabolism TLR3 protein Toll-like receptors Toll-Like Receptors - metabolism Toll样受体 Tumors Vaccination Vaccine 人类介导修饰内化抗原呈递早期细胞亚群
Title	Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells
URI	http://lib.cqvip.com/qk/87787X/201704/671819546.html https://link.springer.com/article/10.1038/cmi.2015.87 https://www.ncbi.nlm.nih.gov/pubmed/26456691 https://www.proquest.com/docview/1892702756 https://www.proquest.com/docview/2760394010 https://www.proquest.com/docview/1826644541 https://www.proquest.com/docview/1897379788 https://pubmed.ncbi.nlm.nih.gov/PMC5380941
Volume	14
WOSCitedRecordID	wos000400900500005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2042-0226 dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0058474 issn: 1672-7681 databaseCode: M7P dateStart: 20080201 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2042-0226 dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0058474 issn: 1672-7681 databaseCode: 7X7 dateStart: 20080201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2042-0226 dateEnd: 20181231 omitProxy: false ssIdentifier: ssj0058474 issn: 1672-7681 databaseCode: BENPR dateStart: 20080201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoC4ILb0poWRmpXJDSJrET2ycEqBWHarVCgPYWOY5DI-0m281upf4PfjAzzqMsW_XCJVLkcRR7xp7PnhchRzyRmcpY5FsDJx1e5MbXMih8VWjJi1Dl3JXz-XkuxmM5napJd-HWdG6V_Z7oNuq8NnhHfhKJJMAq3mHwcXHpY9UotK52JTR2yB5mSWDOdW_S78RoAXRW5UQAikxk2MXnBUyemHmJfl3xMfrSPYSdpvp1CbpiUzttQc5tz8l_zKdOK509-d_xPCWPOzxKP7UC9Izcs9Vz8qCtUHn9gvw-d3HBZeW7EBOAp7Rs7xBnXQAnrQuq6bzOywLQLF2gl0xu6bJeA4ilwDdM99nQVU0t5lKmtsrrpp67thzeLlDsGurmw1_cBENVNLumroIgbf8BCIHMzmbNS_Lj7PT7l69-V8jBN4CnVn6WcW2kDUItYpELE4AEaBnbImGJNniCsdxay0IdMs0zVrCAA5lUHDrwIGevyG5VV_Y1oVFUZHEIJAr0KnTJpNJcFBHjRgQyiz1yMDAzXbQJO9IEFDBmtks88qFnb2q6HOhYimOWOls8kynIRYpykUrhkaOBuP_SrWSHPYPTbv03aSgVBvqJOLm1-Yb5Hnk3NMPCxlnUla3X-AnATpzHPLyLRgkmlJDSI_utZA6_CkgXoLqC3mJDZgcCTCy-2VKVFy7BOChBOPVDz_e9dP81su0ZeHP3EA_IowixkHN3OiS7q-XaviX3zdWqbJYjsiOmwj3liOx9Ph1Pvo3cKv4DY8hRSg
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKAZUL70doASO1F6TQPJzYPiCEgKpVlxWHgvYWHMehkXaT7WYXtP-D38FvZMZ5lGWr3nrguPLY60xmxt_E8yBkl8UilWkYuEaDp8PyTLtKeLkrcyVY7suM2XY-Xwd8OBSjkfy8QX53uTAYVtnZRGuos0rjN_L9gMcedvH2vbfTMxe7RuHtatdCoxGLY7P8CS5b_eboA7zfvSA4-Hjy_tBtuwq4Gg73uZumTGlhPF_xiGdce7AdJSKTx2GsNMJpw4wxoa_8ULE0zMHhBzIhGUxgXhbCutfIdbDjHEPI-Kh38PDG0d5ixxxQayz8Nh_QC8W-nhQYRxa9xti9LbBs5fczOJtWT8M1iLseqfnPda09BQ_u_G_8u0tut3ibvmsU5B7ZMOV9crPpwLl8QH4NbN5zUbo2hQbgNy2ab6TjNkGVVjlVdFJlRQ5onU4xCigzdFYtAKRTkEssZ1rTeUUN1oqmpsyquprYsQx-naJa1dTy352eJ3uVNF1S2yGRNnsAQiAz43H9kHy5EpY8IptlVZonhAZBnkY-kEjADTAlFVIxngch09wTaeSQ7V54kmlTkCSJAWBg5b7YIa86cUp0W-MdW42MExtrEIoE5DBBOUwEd8huT9ytdCHZTidQSWvf6sQXEhMZeRRfOHwubA552Q-D4UIuqtJUC1wCsCFjEfMvo5E85KBowiGPG03otwpIHlwRCbP5io70BFg4fXWkLE5tAXU45D2J_7vXadNfT7bOgaeXP-ILsnV48mmQDI6Gx9vkVoC4z4Z27ZDN-WxhnpEb-se8qGfPrbWg5NtVq9cfnGurNg
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGuL5wv4QNMNL2ghSaixPbDwghRsW0quoDoL1ljuOwSG3SNS2o_4Nfw6_jHCfpKJ32tgceIx87jnMun-1zIWSPxSKVaRi4RsNOh-WZdpXwclfmSrDclxmz5Xy-DfhwKI6P5WiL_O5iYdCtstOJVlFnlcYz8l7AYw-rePteL2_dIkYH_ffTMxcrSOFNa1dOo2GRI7P8Cdu3-t3hAfzr_SDof_ry8bPbVhhwNRj6uZumTGlhPF_xiGdcezA1JSKTx2GsNEJrw4wxoa_8ULE0zGHzD2RCMujAvCyEca-R6xyTllu3wVFnBfD20d5oxxwQbCz8NjbQC0VPTwr0KYveoh_fbdBy5fczsFPrlnED7m56bf5zdWstYv_e_7yW98ndFofTD43gPCBbpnxIbjaVOZePyK-BjYcuSteG1gAsp0VzdjpuA1dplVNFJ1VW5IDi6RS9gzJDZ9UCwDsFfsU0pzWdV9RgDmlqyqyqq4lty-DpFMWtpvZfuNPzILCSpktqKyfSZg5ACGRmPK4fk69XsiRPyHZZleYZoUGQp5EPJBLwBHRJhVSM50HINPdEGjlkZ8VIybRJVJLEADwwo1_skDcdayW6zf2OJUjGifVBCEUCPJkgTyaCO2RvRdyNdCHZbsdcSav36sQXEgMceRRf2HzOeA55vWoGhYarqEpTLXAIwIyMRcy_jEbykEsuhEOeNlKxmiogfNiiSOjN1-RlRYAJ1ddbyuLUJlYH4-9JfO9-J1l_fdnmCjy__BNfkVsgVcngcHi0Q-4ECAetx9cu2Z7PFuYFuaF_zIt69tIqDkpOrlq6_gA1t7QE
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Langerin-mediated+internalization+of+a+modified+peptide+routes+antigens+to+early+endosomes+and+enhances+cross-presentation+by+human+Langerhans+cells&rft.jtitle=Cellular+%26+molecular+immunology&rft.au=Fehres%2C+Cynthia+M&rft.au=Duinkerken%2C+Sanne&rft.au=Bruijns%2C+Sven+Cm&rft.au=Kalay%2C+Hakan&rft.date=2017-04-01&rft.eissn=2042-0226&rft.volume=14&rft.issue=4&rft.spage=360&rft_id=info:doi/10.1038%2Fcmi.2015.87&rft_id=info%3Apmid%2F26456691&rft.externalDocID=26456691
thumbnail_s	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F87787X%2F87787X.jpg